Borderline tumors of the ovary

##plugins.themes.academic_pro.article.sidebar##

Published Dec 30, 2014
Download
pdf
Vol. 92 No. 6 (2014): Issue Jun 2014

##plugins.themes.academic_pro.article.main##

T. Damak
J Ben Hassouna
R. Chargui
A. Gamoudi
M. Hechiche
T. Dhieb
K. Rahal

Abstract

Background: Borderline tumors of the ovary (BOT) were described for the first time by Taylor in 1929. These lesions have a more favorable outcome than do other ovarian cancers. Their prognosis and treatment are still subject of discussion since they occurred more often in young women where the sparing fertility surgery is always considered primarily.

aim: Evaluate the management of patients with borderline ovarian tumors.

methods: A retrospective study was conducted in 40 patients with borderline ovarian tumors treated between January 1, 1991 and December 31, 2004.

results: Median follow-up was 43 months, mean age was 44 years. Initial surgery was conservative in 17 patients and radical in 23 cases. Six patients had residual disease. Serous, mucinous and mixte tumors were observed in 18, 21 and 1 cases respectively. Staging was I, II, III in 26, 5, and 9 cases respectively with two pseudomyxomas. Adjuvant Chemotherapy was given in 3 patients. There was a recurrence in 13 patients and seven died. The 5-year overall survival rate was 78 %. Prognostic factors with an impact on survival rate were age, stage of the disease, histological subtype and residual tumor. Factors with a negative impact on recurrence were age, type of surgery and residual disease. With Cox multivariate analysis, residual tumor is an independent factor for overall survival, on the other hand age and type of surgery were significant for recurrence free survival.

Conclusion: Careful staging followed by complete and radical surgery is mandatory. Unilateral salpingo-oophorectomy with omentectomy and multiple peritoneal biopsies and washing could be indicated in patients with child bearing age. Radical surgery after pregnancy is advised.

Keywords:

Ovary, Tumor, Borderline, prognosis, treatment.

##plugins.themes.academic_pro.article.details##

References

  1. Young RH. A brief history of the pathology of the gonads. Mod Pathol 2005; 18 Suppl 2: S3-S17.
  2. Duvillard P, Bognel C, Charpentier P, Prade M. [Tumors of the ovary of borderline malignancy. What have they become 60 years after their identification?]. Ann Pathol 1990; 10: 73-5.
  3. Changes in definitions of clinical staging for carcinoma of the cervix and ovary: International Federation of Gynecology and Obstetrics. Am J Obstet Gynecol 1987; 156: 263-4.
  4. Wong HF, Low JJ, Chua Y, et al. Ovarian tumors of borderline malignancy: a review of 247 patients from 1991 to 2004. Int J Gynecol Cancer 2007; 17: 342-9.
  5. Morris CR, Liu L, Rodriguez AO, Cress RD, Snipes K. Epidemiologic features of borderline ovarian tumors in California: a population-based study. Cancer Causes Control 2013.
  6. Cusido M, Balaguero L, Hernandez G, et al. Results of the national survey of borderline ovarian tumors in Spain. Gynecol Oncol 2007; 104: 617-22.
  7. Souki DZ, Bouchahda H, Limem W, et al. [Borderline tumors : diagnosis and management : report of 10 cases]. Tunis Med 2010; 88: 312-6.
  8. Messalli EM, Grauso F, Balbi G, et al. Borderline ovarian tumors: features and controversial aspects. Eur J Obstet Gynecol Reprod Biol 2012.
  9. Mahdavi A, Pejovic T, Nezhat F. Induction of ovulation and ovarian cancer: a critical review of the literature. Fertil Steril 2006; 85: 819-26.
  10. Darai E, Teboul J, Walker F, et al. Epithelial ovarian carcinoma of low malignant potential. Eur J Obstet Gynecol Reprod Biol 1996;66: 141-5.
  11. Casey AC, Bell DA, Lage JM, et al. Epithelial ovarian tumors of borderline malignancy: long-term follow-up. Gynecol Oncol 1993; 50: 316-22.
  12. Bell DA, Scully RE. Ovarian serous borderline tumors with stromal microinvasion: a report of 21 cases. Hum Pathol 1990; 21: 397-403.
  13. Manchul LA, Simm J, Levin W, et al. Borderline epithelial ovarian tumors: a review of 81 cases with an assessment of the impact of treatment. Int J Radiat Oncol Biol Phys 1992; 22: 867- 74.
  14. Leake J, Woolas RP, Daniel J, Oram DH, Brown CL. Immunocytochemical and serological expression of CA 125: a clinicopathological study of 40 malignant ovarian epithelial tumours. Histopathology 1994; 24: 57-64.
  15. Michael H, Roth LM. Invasive and noninvasive implants in ovarian serous tumors of low malignant potential. Cancer 1986; 57: 1240-7.
  16. Korner M, Burckhardt E, Mazzucchelli L. Different proportions of aneusomic cells in ovarian inclusion cysts associated with serous borderline tumours and serous high-grade carcinomas support different pathogenetic pathways. J Pathol 2005; 207: 20- 6.
  17. Bonnamy L, Fignon A, Fetissof F, et al. [Borderline tumors of the ovary: a multicenter study in 137 patients]. J Gynecol Obstet Biol Reprod (Paris) 2001; 30: 272-81.
  18. Dexeus S, Labastida R, Dexeus D. Conservative management of epithelial ovarian cancer. Eur J Gynaecol Oncol 2005; 26: 473-8.
  19. Gershenson DM, Silva EG, Levy L, et al. Ovarian serous borderline tumors with invasive peritoneal implants. Cancer 1998; 82: 1096-103.
  20. Romeo M, Pons F, Barretina P, Radua J. Incomplete staging surgery as a major predictor of relapse of borderline ovarian tumor. World J Surg Oncol 2013; 11: 13.
  21. Ayhan A, Guvendag Guven ES, Guven S, Kucukali T. Recurrence and prognostic factors in borderline ovarian tumors. Gynecol Oncol 2005; 98: 439-45.
  22. Camatte S, Morice P, Atallah D, et al. Lymph node disorders and prognostic value of nodal involvement in patients treated for a borderline ovarian tumor: an analysis of a series of 42 lymphadenectomies. J Am Coll Surg 2002; 195: 332-8.
  23. Gershenson DM. Contemporary treatment of borderline ovarian tumors. Cancer Invest 1999; 17: 206-10.
  24. Gershenson DM. Clinical management potential tumours of low malignancy. Best Pract Res Clin Obstet Gynaecol 2002; 16: 513- 27.
  25. Morice P, Camatte S, Rey A, et al. Prognostic factors for patients with advanced stage serous borderline tumours of the ovary. Ann Oncol 2003; 14: 592-8.
  26. Kennedy AW, Hart WR. Ovarian papillary serous tumors of low malignant potential (serous borderline tumors). A long-term follow-up study, including patients with microinvasion, lymph node metastasis, and transformation to invasive serous carcinoma. Cancer 1996; 78: 278-86.
  27. Seidman JD, Sherman ME, Kurman RJ. Recurrent serous borderline tumors of the ovary. Int J Gynecol Pathol 1998; 17: 387-9.
  28. Zanetta G, Chiari S, Rota S, et al. Conservative surgery for stage I ovarian carcinoma in women of childbearing age. Br J Obstet Gynaecol 1997; 104: 1030-5.
  29. Seidman JD, Kurman RJ. Subclassification of serous borderline tumors of the ovary into benign and malignant types. A clinicopathologic study of 65 advanced stage cases. Am J Surg Pathol 1996; 20: 1331-45.
  30. Gupta R, Singh S, Nigam S. Bilateral micropapillary serous carcinoma of the ovary: a case report. Arch Gynecol Obstet 2007; 275: 401-4.
  31. Buttin BM, Herzog TJ, Powell MA, Rader JS, Mutch DG. Epithelial ovarian tumors of low malignant potential: the role of microinvasion. Obstet Gynecol 2002; 99: 11-7.
  32. Kurman RJ, Seidman JD, Shih IM. Serous borderline tumours of the ovary. Histopathology 2005; 47: 310-5.
  33. Morice P. Borderline tumours of the ovary and fertility. Eur J Cancer 2006; 42: 149-58.
  34. Attar E, Berkman S, Topuz S, et al. Evolutive peritoneal disease after conservative management and the use of infertility drugs in a patient with stage IIIC borderline micro-papillary serous carcinoma (MPSC) of the ovary: case report. Hum Reprod 2004; 19: 1472-5.
  35. Yinon Y, Beiner ME, Gotlieb WH, et al. Clinical outcome of cystectomy compared with unilateral salpingo-oophorectomy as fertility-sparing treatment of borderline ovarian tumors. Fertil Steril 2007.
  36. Barakat RR. Borderline tumors of the ovary. Obstet Gynecol Clin North Am 1994; 21: 93-105.
  37. Kaern J, Trope CG, Abeler VM. A retrospective study of 370 borderline tumors of the ovary treated at the Norwegian Radium Hospital from 1970 to 1982. A review of clinicopathologic features and treatment modalities. Cancer 1993; 71: 1810-20.